Bausch Health Companies Inc. (BHC)

In the past six months, Bausch Health's stock price has underperformed the S&P500 Index. Key events impacting the stock include the announcement of Q4 and full-year 2025 results, the Q1 2026 earnings report, a debt refinancing and rating upgrade by Fitch Ratings, insider selling, and the company having negative shareholders equity.

The provided information mentions "BHC Seasonality" and indicates that it displays mean and median monthly returns to identify seasonal patterns. However, specific details regarding the seasonal demand for Bausch Health's products and services are not available.

Bausch Health Companies Inc. is a global, diversified Canadian pharmaceutical company specializing in pharmaceuticals, medical devices, and over-the-counter products, operating in the healthcare sector. The company's business is structured around five main segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. Its diversified portfolio includes products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, medical aesthetics, and eye health.

Bausch Health has a significant global presence, manufacturing and marketing its products in more than 90 countries and regions. Its global corporate headquarters are in Laval, Quebec, Canada, with U.S. headquarters in Bridgewater, New Jersey. The company serves geographic regions including North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

Bausch Health aims to improve people's lives through its healthcare products and be a globally integrated healthcare company. Consistent revenue growth and strategic acquisitions could be seen as positive indicators. A reported impairment and negative shareholders' equity could potentially affect investor confidence and aspects of its reputation.

Institutional investors are the dominant force in Bausch Health Companies Inc.'s ownership. Major institutional shareholders include Paulson & Co. Inc., Goldentree Asset Management Lp, and Vanguard Group Inc. The largest individual shareholder is John Paulson, owning 95.44 million shares, representing 25.76% of the company.